Vimarsana
Biggest News Aggregation in the World

Page 36 - Disease Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Disease Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Disease Program Today - Breaking & Trending Today

Report details cases of leprosy in California - Vimarsana News

Report details cases of leprosy in California

Leprosy is an ancient infectious disease, but it has not been banished to the past, or from the United States.

Source: upi.com
PRESSWIRE 2022/2023: ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights - Vimarsana News

PRESSWIRE 2022/2023: ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

TORONTO, Ontario and CAMBRIDGE, Massachusetts - - ProMIS Neurosciences Inc. , a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded... | May 16, 2023

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 -- Vaccinex,... | May 15, 2023

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights - Vimarsana News

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

15.05.2023 - Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s diseasePresented preclinical data supporting target identification and candidate differentiation across pipeline of antibody ...

ProMIS Neurosciences Announces Full Year 2022 Financial - Vimarsana News

ProMIS Neurosciences Announces Full Year 2022 Financial

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- Completed all preclinical studies and manufacturing to support...